The Federal Agency for Medicines and Health Products appeared before the Belgian House of Representatives on Tuesday 17 June 2025, as part of the hearing on the case of the sperm donor carrying the TP53 gene mutation.
On 17 June 2025, the Federal Agency for Medicines and Health Products (FAMHP) was heard in the Belgian House of Representatives. This hearing is linked to the case of the sperm donor carrying the TP53 gene mutation, but also to the failure to comply with the limit of six women per donor.
Hugues Malonne (Chief Executive Officer), Ethel Mertens (Director General at DG Inspection) and Erik Everaert (Director General at DG POST Authorisation) had the opportunity to explain the dossier.
At the request of the parliamentary committee, the FAMHP gathers the information needed to answer any questions left unanswered.
The presentation used at the hearing is available on our website. A replay of the session is also available on the Belgian House of Representatives website.
We would like to emphasise that we are aware that this is a very sensitive topic. Therefore we would like once again to express our deepest sympathy to the families involved, as well as to all those who called on a fertility centre throughout their journey. We do everything we can to shed light on the situation and to provide you with clear answers.
Contact
For any further information, please send an email to icm@fagg-afmps.be.